NASDAQ:EKSO Ekso Bionics (EKSO) Stock Price, News & Analysis $1.20 +0.02 (+1.69%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Ekso Bionics alerts: Email Address About Ekso Bionics Stock (NASDAQ:EKSO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ekso Bionics alerts:Sign Up Key Stats Today's Range$1.14▼$1.2150-Day Range$0.88▼$1.4952-Week Range$0.65▼$3.13Volume14,437 shsAverage Volume122,314 shsMarket Capitalization$21.81 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingBuy Company OverviewEkso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.Read More… Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Ekso Bionics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks57th Percentile Overall ScoreEKSO MarketRank™: Ekso Bionics scored higher than 57% of companies evaluated by MarketBeat, and ranked 527th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEkso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEkso Bionics has only been the subject of 1 research reports in the past 90 days.Read more about Ekso Bionics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ekso Bionics are expected to grow in the coming year, from ($0.42) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ekso Bionics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ekso Bionics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEkso Bionics has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ekso Bionics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.07% of the outstanding shares of Ekso Bionics have been sold short.Short Interest Ratio / Days to CoverEkso Bionics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ekso Bionics has recently decreased by 46.36%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEkso Bionics does not currently pay a dividend.Dividend GrowthEkso Bionics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.07% of the outstanding shares of Ekso Bionics have been sold short.Short Interest Ratio / Days to CoverEkso Bionics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ekso Bionics has recently decreased by 46.36%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.72 News SentimentEkso Bionics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ekso Bionics this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ekso Bionics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.10% of the stock of Ekso Bionics is held by insiders.Percentage Held by InstitutionsOnly 6.42% of the stock of Ekso Bionics is held by institutions.Read more about Ekso Bionics' insider trading history. Receive EKSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter. Email Address EKSO Stock News HeadlinesEkso Bionics (NASDAQ:EKSO) Receives New Coverage from Analysts at StockNews.comSeptember 25 at 2:59 AM | americanbankingnews.comEkso Bionics Announces Pricing of $6.0 Million Underwritten Public OfferingAugust 29, 2024 | globenewswire.comWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.September 28, 2024 | Weiss Ratings (Ad)Ekso Bionics Holdings, Inc. (0IFR.L)August 21, 2024 | uk.finance.yahoo.comEkso Bionics Announces Receipt of Initial CMS Reimbursement for Ekso Indego PersonalAugust 20, 2024 | finance.yahoo.comEkso Bionics Holdings Second Quarter 2024 Earnings: Revenues DisappointJuly 31, 2024 | finance.yahoo.comQ2 2024 Ekso Bionics Holdings Inc Earnings CallJuly 30, 2024 | finance.yahoo.comMaintaining Buy Rating: Strong Financials and Growth Prospects Justify Positive Outlook for Ekso Bionics Holdings, Inc.July 30, 2024 | markets.businessinsider.comSee More Headlines EKSO Stock Analysis - Frequently Asked Questions How have EKSO shares performed this year? Ekso Bionics' stock was trading at $2.50 on January 1st, 2024. Since then, EKSO stock has decreased by 52.0% and is now trading at $1.20. View the best growth stocks for 2024 here. How were Ekso Bionics' earnings last quarter? Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) announced its quarterly earnings results on Monday, July, 29th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The business earned $4.95 million during the quarter, compared to analyst estimates of $5.34 million. Ekso Bionics had a negative net margin of 68.41% and a negative trailing twelve-month return on equity of 92.08%. When did Ekso Bionics' stock split? Shares of Ekso Bionics reverse split before market open on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. How do I buy shares of Ekso Bionics? Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ekso Bionics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ekso Bionics investors own include Organigram (OGI), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN) and Bionano Genomics (BNGO). Company Calendar Last Earnings7/29/2024Today9/28/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry General industrial machinery, Sub-IndustryMachinery Current SymbolNASDAQ:EKSO Previous SymbolOTCMKTS:EKSOD CUSIPN/A CIK1549084 Webwww.eksobionics.com Phone(510) 984-1761Fax510-927-2647Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.25 High Stock Price Target$10.00 Low Stock Price Target$2.50 Potential Upside/Downside+420.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,200,000.00 Net Margins-68.41% Pretax Margin-68.41% Return on Equity-92.08% Return on Assets-42.83% Debt Debt-to-Equity Ratio0.36 Current Ratio2.42 Quick Ratio1.77 Sales & Book Value Annual Sales$18.16 million Price / Sales1.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book1.41Miscellaneous Outstanding Shares18,174,000Free Float17,065,000Market Cap$21.81 million OptionableOptionable Beta1.45 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:EKSO) was last updated on 9/28/2024 by MarketBeat.com Staff From Our PartnersThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredIt’s over.We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used ...Behind the Markets | SponsoredUrgent 2024 Election Summit [link enclosed]With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ekso Bionics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ekso Bionics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.